ABN AMRO Bank N.V. Makes New Investment in Abbott Laboratories $ABT

ABN AMRO Bank N.V. purchased a new position in shares of Abbott Laboratories (NYSE:ABT) during the 3rd quarter, according to the company in its most recent filing with the SEC. The institutional investor purchased 279,827 shares of the healthcare product maker’s stock, valued at approximately $37,142,000.

Other institutional investors also recently modified their holdings of the company. Norges Bank acquired a new stake in shares of Abbott Laboratories in the second quarter valued at approximately $3,026,180,000. Laurel Wealth Advisors LLC raised its stake in Abbott Laboratories by 13,347.0% in the 2nd quarter. Laurel Wealth Advisors LLC now owns 6,056,934 shares of the healthcare product maker’s stock valued at $823,804,000 after acquiring an additional 6,011,891 shares during the period. Vanguard Group Inc. lifted its holdings in Abbott Laboratories by 1.8% during the 2nd quarter. Vanguard Group Inc. now owns 172,800,851 shares of the healthcare product maker’s stock valued at $23,502,644,000 after purchasing an additional 2,977,715 shares during the last quarter. First Trust Advisors LP increased its holdings in shares of Abbott Laboratories by 180.7% in the second quarter. First Trust Advisors LP now owns 3,063,443 shares of the healthcare product maker’s stock valued at $416,659,000 after purchasing an additional 1,972,097 shares during the last quarter. Finally, TD Asset Management Inc raised its position in shares of Abbott Laboratories by 98.6% in the second quarter. TD Asset Management Inc now owns 3,467,896 shares of the healthcare product maker’s stock valued at $471,669,000 after purchasing an additional 1,721,523 shares during the period. 75.18% of the stock is owned by institutional investors.

Abbott Laboratories Stock Performance

NYSE:ABT opened at $108.18 on Thursday. The company has a quick ratio of 1.24, a current ratio of 1.70 and a debt-to-equity ratio of 0.23. The firm has a market capitalization of $188.11 billion, a PE ratio of 29.08, a price-to-earnings-growth ratio of 1.73 and a beta of 0.75. Abbott Laboratories has a twelve month low of $105.27 and a twelve month high of $141.23. The stock’s 50-day simple moving average is $121.62 and its 200 day simple moving average is $127.11.

Abbott Laboratories (NYSE:ABT) last issued its quarterly earnings data on Thursday, January 22nd. The healthcare product maker reported $1.50 EPS for the quarter, meeting the consensus estimate of $1.50. Abbott Laboratories had a net margin of 14.72% and a return on equity of 17.94%. The business had revenue of $11.46 billion during the quarter, compared to the consensus estimate of $11.80 billion. During the same quarter in the prior year, the firm earned $1.34 EPS. The firm’s revenue was up 4.4% compared to the same quarter last year. Abbott Laboratories has set its Q1 2026 guidance at 1.120-1.180 EPS and its FY 2026 guidance at 5.550-5.800 EPS. On average, analysts anticipate that Abbott Laboratories will post 5.14 EPS for the current fiscal year.

Abbott Laboratories Increases Dividend

The firm also recently announced a quarterly dividend, which will be paid on Friday, February 13th. Investors of record on Thursday, January 15th will be given a dividend of $0.63 per share. This represents a $2.52 annualized dividend and a dividend yield of 2.3%. The ex-dividend date is Thursday, January 15th. This is a positive change from Abbott Laboratories’s previous quarterly dividend of $0.59. Abbott Laboratories’s dividend payout ratio is currently 67.74%.

Analyst Ratings Changes

ABT has been the topic of several research analyst reports. Daiwa Capital Markets lowered their price target on shares of Abbott Laboratories from $136.00 to $113.00 and set an “outperform” rating on the stock in a report on Friday, January 30th. Citigroup dropped their price target on Abbott Laboratories from $155.00 to $140.00 and set a “buy” rating for the company in a report on Friday, January 23rd. Leerink Partners decreased their price objective on Abbott Laboratories from $136.00 to $119.00 and set a “market perform” rating on the stock in a report on Friday, January 30th. BTIG Research lowered their price objective on Abbott Laboratories from $145.00 to $140.00 and set a “buy” rating on the stock in a research report on Friday, January 23rd. Finally, William Blair raised shares of Abbott Laboratories to a “strong-buy” rating in a research report on Thursday, November 20th. Two investment analysts have rated the stock with a Strong Buy rating, sixteen have assigned a Buy rating and four have issued a Hold rating to the company. Based on data from MarketBeat, the stock has an average rating of “Moderate Buy” and a consensus target price of $137.05.

Abbott Laboratories Company Profile

Abbott Laboratories is a global healthcare company headquartered in Abbott Park, Illinois, that develops, manufactures and markets a broad portfolio of medical products and services. Founded in 1888, Abbott operates through multiple business areas that focus on diagnostics, medical devices, nutritionals and established pharmaceuticals. The company supplies hospitals, clinics, laboratories, retailers and direct-to-consumer channels with products intended to diagnose, treat and manage a wide range of health conditions.

In diagnostics, Abbott provides laboratory and point-of-care testing platforms and assays used to detect infectious diseases, chronic conditions and biomarkers; its Alinity family of instruments and rapid-test solutions are examples of this capability.